You are here

  • Home
  • Archive
  • Volume 62, Issue 12
  • Anti-tumour necrosis factor α treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment

Article Text

Article menu
Download PDFPDF
Letter
Anti-tumour necrosis factor α treatment in chronic recurrent inflammation of the anterior segment of the eye in patients resistant to standard immunomodulatory treatment
  1. Y El-Shabrawi1,
  2. H Mangge2,
  3. J Hermann3
  1. 1Department of Ophthalmology, Karl-Franzens University, Graz, Austria
  2. 2Department of Laboratory Medicine and Paediatric Immunology/Rheumatology, Karl-Franzens University, Graz, Austria
  3. 3Department of Internal Medicine, Karl-Franzens University, Graz, Austria
  1. Correspondence to:
    Dr Y El-Shabrawi
    Department of Ophthalmology, Karl Franzens University Hospital, Auenbruggerplatz 4, 8036 Graz, Austria; yosuf.elshabrawikfunigraz.ac.at

https://doi.org/10.1136/ard.2003.008615

Statistics from Altmetric.com

    Recurrent or chronic anterior uveitis leads to a drop of vision below 20/50 in 23% of patients; 11% will eventually be legally blind.1,2 Thus the treatment of these patients still presents a challenge, and additional treatments are needed. In a previous study we found that anti-tumour necrosis factor α (anti-TNFα) treatment was highly efficient in a patient with an acute HLA-B27 associated uveitis.3 Thus we tested the efficacy of anti-TNFα treatment, consisting of a combined immunomodulatory drug and corticosteroids, in chronic inflammatory diseases of the anterior segment of the eye, non-responsive to standard anti-inflammatory treatment.

    PATIENTS

    Nine patients with uveitis with associated systemic disease were included (table 1). Eight of these patients had a rheumatic disease (five had a spondyloarthropathy (all were HLA-B27 positive), two had juvenile idiopathic arthritis (JIA; one Still’s disease, …

    View Full Text